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Background: Despite declines in mortality and morbidity rates of patients with human immunodeficiency virus (HIV) infection as the 
result of highly active antiretroviral therapy, liver diseases due to chronic hepatitis B virus (HBV) and hepatitis C virus (HCV) infections 
are a leading cause of death among HIV-infected patients. However, HIV and HBV or HCV coinfection is still poorly documented, 
and more information is needed to better understand the characteristics of HIV-infected patients in Korea. 
Materials and Methods: A cross-sectional study was performed to investigate clinical characteristics and prevalence of HBV and 
HCV infection in HIV patients enrolled in the Korea HIV/acquired immune deficiency syndrome (AIDS) cohort study from 17 institu-
tions between December 2006 and July 2013. 
Results: Among the 1,218 HIV-infected participants, 541 were included in this study. The prevalence of HBV-HIV and HCV-HIV coin-
fection was 5.0% (27/541) and 1.7% (9/541), respectively. There was no patient who was positive for both HBs antigen and HCV an-
tibody. In multivariate logistic regression analysis, HBV unvaccinated status was a significant risk factor for HBV-HIV coinfection (odds 
ratio = 4.95, 95% confidence interval = 1.43–17.13). 
Conclusion: HBV and HCV infection was more common in HIV-infected persons enrolled in the Korean HIV/AIDS cohort, than 
in the general population in Korea. 
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Introduction
Therapy for human immunodeficiency virus (HIV)-infected 
patients has progressed remarkably since the introduction of 
antiretroviral therapy (ART). Furthermore, since the early start 
of effective ART, the incidence of opportunistic infections as 
well as the mortality rate in patients with HIV has decreased 
[1-3]. Liver disease is currently the major concern in HIV-in-
fected patients coinfected with hepatitis B virus (HBV) or hep-
atitis C virus (HCV) [4, 5]. HBV-HIV or HCV-HIV patients have 
more rapid progression of liver disease than those with HBV 
or HCV mono-infection. End-stage liver disease, such as liver 
cirrhosis or hepatocellular carcinoma, is commonly observed 
in patients with HBV-HIV or HCV-HIV coinfection [6-9]. Fur-
thermore, HBV or HCV coinfection may increase the risk of 
ART-related hepatotoxicity or influence the selection of ART 
regimen [10]. 
HIV and HBV or HCV coinfection is still poorly documented 
in Korea. Although some studies have evaluated viral hepatitis 
coinfection in HIV-infected patients, these were retrospective 
single-center studies and reported little data about HBV-HIV 
coinfection [11, 12]. Thus, more information is needed to bet-
ter understand the characteristics of HIV-infected patients in 
Korea. 
We therefore conducted a prospective multicenter study to 
investigate the prevalence and epidemiological features of 
both HBV and HCV coinfections among HIV-infected Korean 
patients.
Materials and Methods
1. Study design and population
The Korea HIV/acquired immune deficiency syndrome 
(AIDS) cohort study is a prospective multicenter study with 
ongoing enrollment of HIV-infected adult patients older than 
18 years from 17 hospitals in South Korea (Gachon University 
Gil Hospital, Seoul St. Mary’s Hospital, Hallym University 
Kangdong Sacred Heart Hospital, Kyungpook National Uni-
versity Hospital, Korea University Guro Hospital, Korea Uni-
versity Ansan Hospital, Seoul Asan Hospital, Soon Chun 
Hyang University Hospital Seoul, Ajou University Hospital, 
Severance Hospital, Wonju Severance Christian Hospital, 
Ewha Womans University Mokdong Hospital, Inha University 
Hospital, Chungbuk National University Hospital, Hallym 
University Anyang Sacred Heart Hospital, Hallym University 
Kangnam Sacred Heart Hospital, and Yeungnam University 
Hospital). To evaluate the prevalence and epidemiological 
features of HBV or HCV coinfection among HIV-infected per-
sons, we investigated the presence of HBV surface antigen 
(HBs Ag) and anti-HCV antibody (Ab). Patients who tested 
negative for HBs Ag and anti-HCV Ab were defined as HIV 
mono-infection patients. Among patients with HIV infection, 
HBV coinfection was defined based on positive test results for 
HBs Ag and HCV coinfection was defined based on positive 
test results for anti-HCV Ab. Trained researchers from all cen-
ters prospectively collected information every 6 months using 
a standardized protocol. Information included medical histo-
ry, socioeconomic status, physical findings, laboratory find-
ings including immunological and virological status, and op-
portunistic diseases. All participants provided written 
informed consent and ethics approval was obtained from the 
Institutional Review Board of each participating institute. This 
study analyzed data for 1,218 HIV-infected persons enrolled 
between December 2006 and July 2013.
2. Laboratory tests and data collection
HIV infection was screened for using enzyme immunoas-
says (EIA) and confirmed using western blotting. HBV infec-
tion was defined based on HBs Ag positivity without protec-
tive antibodies. HCV infection was detected via EIA for 
anti-HCV Ab presence, and reactive samples were confirmed 
using recombinant immunoblot assay. To evaluate the preva-
lence and epidemiological features of HBV or HCV coinfec-
tions, we used baseline data at the time of registration in the 
Korea HIV/AIDS cohort study. These data included age, sex, 
body mass index, race, socioeconomic status, sexual habit, 
first year of HIV diagnosis, history of smoking and alcohol use, 
route of transmission, CD4/CD8 count, HIV viral load, ART 
history, HBV vaccination status, history of liver disease, and 
serum chemistry at study enrollment.
3. Statistical analysis
Continuous variables are presented as medians with inter-
quartile ranges (IQR) and categorical variables are expressed 
as numbers with percentages. To compare variables between 
two groups, an independent sample t-test or the Mann-Whit-
ney U test was used for continuous variables, and a Brown-
Mood median two-sample test or Fisher’s exact test was used 
for categorical variables. Factors associated with HBV or HCV 
coinfection were analyzed by univariate and multivariate lo-
gistic regression models. Variables with a P value less than 0.25 
in baseline characteristic analyses were included in univariate 
analyses, and multivariate analyses included variables with a 
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P value less than 0.16 in univariate analyses. The relationships 
between clinical factors and HBV or HCV coinfection were 
summarized by odds ratios (ORs) and 95 % confidence inter-
vals (CIs). Statistical analyses were performed using the SPSS, 
version 16.0 (SPSS Inc., Chicago, IL, USA). A P value less than 
0.05 was considered statistically significant.
Results
1. Baseline characteristics of patients
Among 1,218 participants, 677 were excluded because of 
missing data. 541 participants were included for analysis. The 
prevalence of HBV and HCV coinfection was 5.0% (27/541) 
and 1.7% (9/541), respectively (Fig. 1). The baseline character-
istics of the 541 HIV-infected patients are shown in Table 1. 
Most patients were men (92.8%) and of Korean ethnicity 
(98.7%). The median age was 42 years (IQR, 33–51 years). Ac-
cording to a self-reported questionnaire, HIV was transmitted 
mainly by sexual contact (97.6%), and the proportion of ho-
mosexual patients (33.1%) was similar to that of heterosexual 
patients (36.4%). The median CD4 cell count was 356 cells/
mm3 (IQR, 206–512 cells/mm3) and the median HIV viral load 
was 157 copies/mL (IQR, 20–19,645 copies/mL). 375 patients 
(69.3%) were treatment naïve. 
Among the 541 HIV patients who had results of HBs Ag and 
anti-HCV Ab testing, 36 patients (6.7%) had HBV or HCV coin-
fection. There were significant differences in age, sex, trans-
mission route of HIV, history of liver cirrhosis, and HBV vacci-
nation status between HIV mono-infection patients and HBV 
Total number of patients
N = 1,218
Excluded (n = 300)
* Missing of age (n=1)
* Missing of race (n=1)
* Missing of ART (n=8)
* Missing of Current CD4 (n=220)
* Missing of Current RNA (n=70)
Patients who has current CD4 and RNA
(n = 918)
Excluded (n = 377)
* Missing of BMI (n=221)
* Missing of Smoking and Drinking status (n = 49)
* Missing of AST/ALT/Total bililubin (n=12)
* Missing of disease history related liver (n=10)
* Missing of viral hepatitis (HBsAg) results (n=85)
541 participants were
included for analysis
HIV mono 
infection
n = 505
HBV only
n = 27
HCV only
n = 9
Hepatitis coinfection
n = 36
Figure 1. Profile of enrolled patients. 
ART, antiretroviral therapy; RNA, ribonucleic acid; BMI, body mass index; AST, aspartate transaminase; ALT, alanine transaminase; HIV, 
human immunodeficiency virus; HBV, hepatitis B virus; HCV, hepatitis C virus.
n 1,
n = 
HIV mono
infection
n = 505
HIV only
n = 27
HCV only
n = 9
* is  of age (n = 1)
* is  of race (n = 1)
* is  of ART (n = 8)
* is  of Current CD4 (n = 220)
* is i  of Curremt RNA (n = 70)
issing of BMI (n = 221)
* issing of Smoking and Drinking status (n = 49)
* issing of AST/ALT/Total bililubin (n = 12)
* issing of disease history related liver (n = 10)
* issing of viral hepatitis (HBsAg) results (n = 85)
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Table 1. Patients’ baseline characteristics
Variables
n (%)
P-value
Total HIV mono infection Hepatitis coinfection
n 541 (100.0) 505 (93.4) 36 (6.7) <0.0001
Age (yrs)a 42 (33−51) 41 (33−50) 45 (37−51.5) 0.039b
<30 91 (16.8) 86 (17.0) 5 (13.9) 0.077
<40 151 (27.9) 145 (28.7) 6 (16.7)
<60 252 (46.6) 228 (45.2) 24 (66.7)
≥60 47 (8.7) 46 (9.1) 1 (2.8)
Sex 　 　 　 　
Male 502 (92.8) 472 (93.5) 30 (83.3) 0.037c
Female 39 (7.2) 33 (6.5) 6 (16.7)
Race 　 　 　 　
Korean 534 (98.7) 500 (99.0) 34 (94.4) 0.073c
Foreigner 7 (1.3) 5 (1.00) 2 (5.7)
Transmission route of HIV 　 　 　 　
Reception of blood/product 1 (0.2) 0 (0.0) 1 (0.2) 0.042c
Others (include unknowing)d 12 (2.2) 11 (2.2) 1 (2.8)
Sexual contact 528 (97.6) 494 (97.8) 34 (94.4)
Homosexual 179 (33.1) 173 (33.7) 6 (22.2) 0.179
Heterosexual 197 (36.4) 182 (35.4) 15 (55.6)
Bisexual 152 (28.1) 146 (28.4) 6 (22.2)
Baseline CD4 cell count (cells/mm3)a 356 (206−512) 360 (208−512) 310 (175−501.5) 0.306b 
Baseline HIV RNA (copies/mL)a 157 (20−19,645) 196 (20−17,415) 74.5 (20−26,574) 0.307b
Treatment naïve 375 (69.3) 348 (68.9) 27 (75.0) 0.444
Body mass index (BMI, kg/m2) 　 　 　 　
Mean ± SD 22.2 ± 2.91 22.2  ± 2.91 21.9 ± 2.94 0.305b
Median (IQR) 21.8 (20.31−23.88) 21.85 (20.32−23.88) 21.56 (19.72−23.94)
Smoking history 　 　 　 　
Current 267 (49.4) 251 (49.7) 16 (44.4) 0.086
Previous 99 (18.3) 96 (19.0) 3 (8.3)
Non smoker 175 (32.4) 158 (31.3) 17 (47.2)
Alcohol history 　 　 　 　
Current 285 (52.7) 270 (53.5) 15 (41.7) 0.380
Previous 91 (16.8) 84 (16.6) 7 (19.4)
Non drinker 165 (30.5) 151 (29.9) 14 (38.9)
Laboratory resultsa 　 　 　 　
AST (IU/L) 22 (18−30) 22 (18−30) 23 (20−28.5) 0.660b
ALT (IU/L) 21 (15−32) 21 (15−33) 20.5 (15.6−26.0) 0.403b
Total bilirubin (mg/dL) 0.60 (0.43−0.90) 0.60 (0.43−0.90) 0.57 (0.455−0.805) 0.122b
Liver disease 　 　 　 　
Fatty liver 6 (1.1) 5 (1.0) 1 (2.8) 0.267c
Liver cirrhosis 4 (0.7) 1 (0.2) 3 (8.3) 0.001c
Values are presented as medians (interquartile ranges (IQR)) or numbers (percentages).
HIV, human immunodeficiency virus; RNA, ribonucleic acid; SD, standard deviation; IQR, interquartile range; AST, aspartate transaminase; ALT, alanine transaminase.
aMedian (Interquartile range, IQR). 
bBrown-Mood’s median two-sample test.
cFisher's exact test.
dOthers include vertical transmission and unknowing.
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or HCV coinfection patients. Patients with HBV or HCV coin-
fection were older than HIV mono-infection patients (median, 
45 years; IQR, 37–51 years vs. median, 41 years; IQR, 33–50 
years, P <0.039). Patients with liver cirrhosis were more com-
mon in the HBV or HCV coinfection group than the HIV mo-
no-infection group (8.3% vs. 0.2%, P = 0.001). In contrast, male 
sex was more common in the HIV mono-infection patients 
than the HBV or HCV coinfection patients (93.5% vs. 83.3%, P 
= 0.037), and the rate of HBV vaccination was significantly dif-
ferent between the HIV mono-infection group and HBV or 
HCV coinfection group (P = 0.0002). 
2. Factors associated with HBV and HCV coinfection
Univariate logistic regression analysis showed that age, sex, 
sexual contact, history of liver cirrhosis, and HBV vaccination 
status were associated with HBV coinfection in HIV patients 
(Table 2). Sexuality and history of liver cirrhosis were not in-
cluded in multivariate analysis because of unmatched num-
ber of participants. In multivariate analysis, HBV unvaccinat-
ed status was an independent risk factor for HBV coinfection 
(OR = 4.95, 95% CI = 1.43–17.13). Factors associated with HCV 
coinfection were not analyzed because of small number of 
HCV coinfection patients. 
Discussion
In this study, we investigated the prevalence and epidemio-
logical features of HBV and HCV coinfection in HIV-infected 
Korean patients. The rate of HBV or HCV coinfection in HIV 
patients was 6.7%. The prevalence of HBV-HIV coinfection 
and HCV-HIV coinfection was 5.0% and 1.7%, respectively. 
Multivariate logistic regression analysis showed that the risk 
of HBV coinfection was associated with HBV unvaccinated 
status. Factors associated with HCV infection were not identi-
fied in this study because of small number of HCV coinfection 
patients.
Previous studies have reported hepatitis virus coinfection 
among HIV-infected Korean patients [11, 12]. However, they 
did not report the demographic characteristics of patients 
with HBV-HIV coinfection. To the best of our knowledge, our 
study is the first to evaluate the prevalence and demographic 
characteristics of both HBV-HIV and HCV-HIV coinfections in 
HIV-infected Korean patients.
HBV or HCV infection in HIV patients is more common than 
in the general population [13]. This may be caused by similari-
ties in routes of transmission and risk factors between HBV or 
HCV and HIV, for example, injection drug use, sexual contact, 
and reception of blood products [14-16]. Our study also showed 
Table 2. Factors associated with hepatitis B virus coinfection
Variables
HBV coinfection (n = 104)
Univariate OR (95 % CI) P-value Multivariate OR (95% CI) P-value
Age (years) (vs. <42a)
≥42 2.06 (0.91–4.68) 0.083 1.52 (0.63–3.65) 0.353
Male sex (vs. female sex) 0.42 (0.114–1.28) 0.128 0.59 (0.17–2.05) 0.405
Race (vs. foreigner)
Korean 0.31 (0.04–2.65) 0.283
Sexuality (vs. homosexual)
Heterosexual 2.38 (0.90–6.27) 0.587
Bisexual 1.19 (0.37–3.75) 0.05
Smoking history (vs. nonsmoker)
Current 0.76 (0.33–1.74) 0.799
Previous 0.47 (0.13–1.71) 0.313
Liver disease (vs. no)
Liver cirrhosis 64.10 (6.43–639.12) 0.0004
HBV vaccination (vs. yes)
No 6.28 (1.85–21.32) 0.0005 4.95 (1.43–17.13) 0.001
Unknown 1.09 (0.18–6.63) 0.286 0.69 (0.10–4.79) 0.17
Values are presented as medians (interquartile ranges) or numbers (percentages).
HBV, hepatitis B virus; OR, odds ratio; CI, confidence interval.
aMedian criteria.
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a higher prevalence of HBV or HCV infection in HIV patients 
than in the general population. According to the Korea National 
Health and Nutrition Examination Survey, the HBV infection 
rate in the general population is 2.9% [17]. Kim et al. reported 
that the nationwide prevalence of HCV in Korea was 0.78% [18]. 
The rates of HBV or HCV coinfection among HIV patients 
have been studied in several countries [19-23]. The prevalence 
of HBV-HIV coinfection reported in our study is similar to that 
of other countries [19]. However, we found a lower prevalence 
of HCV-HIV coinfection than that reported in previous studies 
[24, 25]. A possible cause is that the regions from which pa-
tients were drawn for this study did not include regions with a 
high prevalence of anti-HCV. A Korean study, implemented in 
a region with a high prevalence of anti-HCV, reported an HCV-
HIV coinfection prevalence of 5.2% [12]. 
Our study had several limitations. First, we did not show the 
factors associated with HCV-HIV coinfection because of small 
number of patients with HCV-HIV coinfection. Second, our 
HCV-HIV coinfection data is insufficient to represent the char-
acteristics of HCV-HIV coinfection throughout Korea because 
we did not include the institutions in regions with a high prev-
alence of HCV-HIV coinfection. Third, a large number of par-
ticipants were excluded due to missing data. Therefore, there 
is a possibility of selection bias. Also, there is the potential for 
recall bias because the history of HBV vaccination was con-
firmed by questionnaire to the participants. Further studies 
are required to be conducted with nationwide and accurate 
data for HBV and HCV coinfection. 
In conclusion, this study showed that the prevalence of HBV 
and HCV infection in HIV patients was higher than that in the 
Korean general population. The prevalence of HBV-HIV coin-
fection was higher than that of HCV-HIV coinfection. HBV un-
vaccinated status was an independent risk factor for HBV-HIV 
coinfection. A nationwide study is needed to analyze the prev-
alence and epidemiological features of HCV-HIV coinfection 
in the Korean population as a whole. 
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